Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: September 17, 2004
Last updated: May 6, 2013
Last verified: May 2013
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.

Condition Intervention Phase
Drug: Darbepoetin Alfa
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Occurrences of red blood cell transfusion [ Time Frame: from study day 29 (week 5) to week 17 ]

Secondary Outcome Measures:
  • Incidence of first red blood cell transfusion [ Time Frame: from week 5 (study day 29) to week 17 (study day 119) ]
  • Change in hemoglobin concentration measured [ Time Frame: from baseline (study day 1) to EOTP ]
  • Adverse events and serious adverse events [ Time Frame: throughout study for subjects who received at least 1 dose of investigational product ]
  • Survival [ Time Frame: deaths on study and deaths in long-term follow-up period for subjects who received at least 1 dose of investigational product ]
  • Incidence, if any, of neutralizing antibody formation to investigational product [ Time Frame: throughout study for subjects who received at least 1 dose of investigational product ]

Estimated Enrollment: 1000
Study Start Date: April 2004
Study Completion Date: December 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Darbepoetin alfa 6.75 mcg/kg Q4W Drug: Darbepoetin Alfa
6.75 mcg/kg Q4W
Placebo Comparator: Placebo Q4W Drug: Placebo
Placebo Q4W


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • subjects with non-myeloid malignancies
  • anemia due to cancer
  • ECOG status 0 to 2
  • greater than or equal to 4-month expectancy
  • greater than or equal to 18 years and of legal age for informed consent
  • screening hemoglobin concentration less than or equal to 11.0g/dL
  • adequate serum folate and vitamin B12
  • adequate renal and liver function
  • written informed consent

Exclusion Criteria:

  • subjects currently receiving or planned to receive cytotoxic chemotherapy or myelosuppressive radiotherapy during the study or within 4 weeks before randomization
  • in complete remission, as determined by the investigator
  • subjects who have other diagnoses not related to the cancer which cause anemia (eg. gastrointestinal bleeding, renal disease, etc)
  • documented history of pure red cell aplasia
  • Known history of seizure disorder
  • cardiac condition: uncontrolled angina, congestive heart failure, known ejection fraction less than 40%, or uncontrolled cardiac arrhythmia
  • uncontrolled hypertension
  • clinically significant systemic infection or chronic inflammatory disease present at the time of randomization
  • iron deficiency
  • known positive test for HIV infection
  • previously suspected of or confirmed to have neutralizing antibodies to rHuEPO or darbepoetin alfa
  • received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization
  • less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority
  • pregnant or breast feeding
  • subject of reproductive potential who is not using adequate contraceptive precautions
  • known hypersensitivity to mammalian-derived product or any other ingredients in the investigational product
  • previously randomized into this study
  • concerns for subject's compliance with the protocol procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00091858

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT00091858     History of Changes
Obsolete Identifiers: NCT00098696
Other Study ID Numbers: 20010103
Study First Received: September 17, 2004
Last Updated: May 6, 2013

Keywords provided by Amgen:
Cancer-related anemia

Additional relevant MeSH terms:
Hematologic Diseases
Darbepoetin alfa
Hematinics processed this record on May 25, 2017